Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL

Patients with indolent B-cell non-Hodgkin lymphoma (iNHL) generally require treatment but experience normal survival, emphasizing the need for simpler, safer therapies. Proteasome inhibitors target aberrant signaling pathways within iNHL and have manageable toxicities. We evaluated the oral proteaso...

Descripción completa

Detalles Bibliográficos
Autores principales: Graf, Solomon A., Lynch, Ryan C., Ujjani, Chaitra S., Gooley, Ted A., Rasmussen, Heather, Coffey, David G., Cowan, Andrew J., Smith, Stephen D., Shadman, Mazyar, Warren, Edus H., Libby, Edward N., Greninger, Alexander L., Fromm, Jonathan R., Gopal, Ajay K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984960/
https://www.ncbi.nlm.nih.gov/pubmed/36385536
http://dx.doi.org/10.1182/bloodadvances.2022008628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984960/
https://www.ncbi.nlm.nih.gov/pubmed/36385536
http://dx.doi.org/10.1182/bloodadvances.2022008628

Ejemplares similares